Logo image of KOD

KODIAK SCIENCES INC (KOD) Stock Fundamental Analysis

NASDAQ:KOD - Nasdaq - US50015M1099 - Common Stock - Currency: USD

3.4  -0.17 (-4.76%)

After market: 3.4 0 (0%)

Fundamental Rating

2

Overall KOD gets a fundamental rating of 2 out of 10. We evaluated KOD against 560 industry peers in the Biotechnology industry. The financial health of KOD is average, but there are quite some concerns on its profitability. KOD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KOD has reported negative net income.
In the past year KOD has reported a negative cash flow from operations.
KOD had negative earnings in each of the past 5 years.
KOD had a negative operating cash flow in each of the past 5 years.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

KOD has a worse Return On Assets (-63.99%) than 60.71% of its industry peers.
The Return On Equity of KOD (-175.14%) is worse than 64.82% of its industry peers.
Industry RankSector Rank
ROA -63.99%
ROE -175.14%
ROIC N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KOD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for KOD remains at a similar level compared to 1 year ago.
The number of shares outstanding for KOD has been increased compared to 5 years ago.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -7.66, we must say that KOD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KOD (-7.66) is worse than 69.11% of its industry peers.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.66
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.62 indicates that KOD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.62, KOD is in line with its industry, outperforming 51.61% of the companies in the same industry.
A Quick Ratio of 4.62 indicates that KOD has no problem at all paying its short term obligations.
KOD has a Quick ratio (4.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.62
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

KOD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.06%, which is quite good.
EPS 1Y (TTM)18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KOD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.11% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.78%
EPS Next 2Y-0.83%
EPS Next 3Y-1.61%
EPS Next 5Y9.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KOD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KOD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.83%
EPS Next 3Y-1.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KOD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KODIAK SCIENCES INC

NASDAQ:KOD (5/30/2025, 8:10:30 PM)

After market: 3.4 0 (0%)

3.4

-0.17 (-4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12
Inst Owners80.49%
Inst Owner Change2.11%
Ins Owners5.66%
Ins Owner Change0%
Market Cap179.38M
Analysts48.33
Price Target7.4 (117.65%)
Short Float %7.18%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.37%
Min EPS beat(2)-20.72%
Max EPS beat(2)5.97%
EPS beat(4)3
Avg EPS beat(4)-1.09%
Min EPS beat(4)-20.72%
Max EPS beat(4)7.98%
EPS beat(8)5
Avg EPS beat(8)-4.46%
EPS beat(12)8
Avg EPS beat(12)-0.38%
EPS beat(16)8
Avg EPS beat(16)-4.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.57%
PT rev (3m)3.57%
EPS NQ rev (1m)-6.28%
EPS NQ rev (3m)3.46%
EPS NY rev (1m)-4.6%
EPS NY rev (3m)-2.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-3.63
EYN/A
EPS(NY)-3.42
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS2.06
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.99%
ROE -175.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.62
Altman-Z -7.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)469.16%
Cap/Depr(5y)1839.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.93%
EPS Next Y-16.78%
EPS Next 2Y-0.83%
EPS Next 3Y-1.61%
EPS Next 5Y9.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.92%
EBIT Next 3Y-22.55%
EBIT Next 5YN/A
FCF growth 1Y57.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.27%
OCF growth 3YN/A
OCF growth 5YN/A